Sergey Kuranov

Dr. Sergey Kuranov

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2018 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SKSergey Kuranov
Sergey Kuranov
ITInna Tsypysheva
Inna Tsypysheva
Mikhail KhvostovMikhail Khvostov
Mikhail Khvostov
LZLiana F. Zainullina
Liana F. Zainullina
Sophia S. BorisevichSophia S. Borisevich
Sophia S. Borisevich
NSN.F. Salakhutdinov
N.F. Salakhutdinov

13 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
ESEvgenii Suslov
Evgenii Suslov
KPKonstantin Ponomarev
Konstantin Ponomarev
OPOksana Patrusheva
Oksana Patrusheva
SKSergey Kuranov
Sergey Kuranov
AOAlina Okhina
Alina Okhina
NSNariman F. Salakhutdinov
Nariman F. Salakhutdinov
A number of new chiral bispidines containing monoterpenoid fragments have been obtained. The bispidines were studied as ligands for Ni-catalyzed addition of diethylzinc to chalcones. The conditions for chromatographic analysis by HPLC-UV were developed, in which the peaks of the enantiomers of all synthesized chiral products were separated, which made it possible to determine the enantiomeric excess of the resulting mixture. It was demonstrated that bispidine-monoterpenoid conjugates can be used as the ligands for diethylzinc addition to chalcone C=C double bond but not as inducers of chirality. Besides products of ethylation, formation of products of formal hydrogenation of the chalcone C=C double bond was observed in all cases. Note, that this formation of hydrogenation products in significant amounts in the presence of such catalytic systems was found for the first time. A tentative scheme explaining the formation of all products was proposed.

19 November 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SKSergey Kuranov
Sergey Kuranov
OLOlga Luzina
Olga Luzina
Mikhail KhvostovMikhail Khvostov
Mikhail Khvostov
DBDmitry Baev
Dmitry Baev
DKDarya Kuznetsova
Darya Kuznetsova
NSNariman F. Salakhutdinov
Nariman F. Salakhutdinov
A series of bornyl derivatives of p-(benzyloxy)phenylpropionic acid were prepared, and their hypoglycemic activities were examined by an oral glucose tolerance test in mice. The results of this test revealed two compounds, 1 and 3, that can reduce the blood level of glucose similarly to reference compound vildagliptin. Both compounds were tested in an experiment on mice with metabolic disorders: the C57BL/6Ay strain. Along with hypoglycemic properties, the two compounds showed different abilities to correct lipid metabolism disorders. In silico prediction revealed that the studied substances are most likely bifunctional multitarget hypoglycemic compounds whose mechanism of action is based on a pronounced reduction in insulin resistance and a strong incretin-mimetic effect. The difference in the size of effects of these compounds on biochemical parameters of blood in the experiment on C57BL/6Ay mice was in good agreement with the computational prediction of the priority ranking of biological targets for these compounds. These results indicate that bornyl derivatives of p-(benzyloxy)phenylpropionic acid have a good potential as new agents for diabetes mellitus treatment due to their hypoglycemic and lipid-normalizing properties.

Verified
Journal Article
Open access
PDF file
MBMikhail Blokhin
Mikhail Blokhin
SKSergey Kuranov
Sergey Kuranov
Mikhail KhvostovMikhail Khvostov
Mikhail Khvostov
Vladislav V. FomenkoVladislav V. Fomenko
Vladislav V. Fomenko
OLOlga Luzina
Olga Luzina
NSNariman F. Salakhutdinov
Nariman F. Salakhutdinov
Metabolic syndrome is a complex of abnormalities involving impaired glucose and lipid metabolism, which needs effective pharmacotherapy. One way to reduce lipid and glucose levels associated with this pathology is the simultaneous activation of nuclear PPAR-alpha and gamma. For this purpose, we synthesized a number of potential agonists based on the pharmacophore fragment of glitazars with the inclusion of mono- or diterpenic moiety in the molecular structure. The study of their pharmacological activity in mice with obesity and type 2 diabetes mellitus (C57Bl/6Ay) revealed one substance that was capable of reducing the triglyceride levels in the liver and adipose tissue of mice by enhancing their catabolism and expressing a hypoglycemic effect connected with the sensitization of mice tissue to insulin. It has also been shown to have no toxic effects on the liver.

3 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
DPDarya Pon`kina
Darya Pon`kina
SKSergey Kuranov
Sergey Kuranov
Mikhail KhvostovMikhail Khvostov
Mikhail Khvostov
NZNataliya Zhukova
Nataliya Zhukova
YMYulia Meshkova
Yulia Meshkova
NSNariman F. Salakhutdinov
Nariman F. Salakhutdinov
Free fatty acid receptor-1 (FFAR1) is one of the possible therapeutic targets in the search for new hepatoprotective drugs. FFAR1 agonists were found to have hypolipidemic, antifibrotic, anti-inflammatory, antiproliferative and antioxidant effects in addition to hypoglycemic action. In this work, we conducted a study of the hepatoprotective effect of the compound QS-528 (previously discovered as an agonist of FFAR1) at doses of 60, 90, 120 and 150 mg/kg on carbon tetrachloride (CCl4)-induced liver injury. At the end of the experiment, a biochemical blood assay demonstrated that the introduction of QS-528 dose-dependently reduces the levels of liver enzymes (AST, ALT and ALKP). Histological and morphometric studies of animals’ livers treated with QS-528 at doses of 120 and 150 mg/kg showed a decrease in degenerative/necrotic changes in hepatocytes and an increase in the regenerative activity of the liver. In addition, no toxicity at a single oral dose of 1000 mg/kg and an increase in HepG2 cell viability in vitro were found. Thus, the compound QS-528 was found to exhibit a hepatoprotective effect against CCl4-induced toxic liver damage.

7 June 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DPDarya Pon`kina
Darya Pon`kina
SKSergey Kuranov
Sergey Kuranov
MMMariya Marenina
Mariya Marenina
YMYulia Meshkova
Yulia Meshkova
NZNataliya A. Zhukova
Nataliya A. Zhukova
NSNariman F. Salakhutdinov
Nariman F. Salakhutdinov
Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases worldwide. Several classes of hypoglycemic drugs are used to treat it, but various side effects limit their clinical use. Consequently, the search for new anti-diabetic agents remains an urgent task for modern pharmacology. In this investigation, we examined the hypoglycemic effects of bornyl-containing benzyloxyphenylpropanoic acid derivatives (QS-528 and QS-619) in a diet-induced model of T2DM. Animals were given the tested compounds per os at a dose of 30 mg/kg for 4 weeks. At the end of the experiment, compound QS-619 demonstrated a hypoglycemic effect, while QS-528 showed hepatoprotection. In addition, we performed a number of in vitro and in vivo experiments to study the presumed mechanism of action of the tested agents. Compound QS-619 was determined to activate the free fatty acid receptor-1 (FFAR1) similarly to the reference agonist GW9508 and its structural analogue QS-528. Both agents also increased insulin and glucose-dependent insulinotropic polypeptide concentrations in CD-1 mice. Our results indicate that QS-619 and QS-528 are probably full FFAR1 agonists.